Original Research Article

A study of effectiveness of addition of drug teneligliptin to metformin, glimepiride, pioglitazone combination in type II diabetic patients

Dilip Pandurang Patil*

Department of Medicine, Krishna Institute of Medical Sciences, Deemed to be University, Karad, Maharashtra, India

Received: 13 December 2019
Revised: 19 December 2019
Accepted: 07 January 2020

*Correspondence:
Dr. Dilip Pandurang Patil,
E-mail: patilhospitalkarad@gmail.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Background: Diabetes is a most prevalent chronic disease and has reached to alarming stage in almost all developed and developing countries. Worldwide approximately four hundred millions of people are living with diabetes and it is a leading cause of death. Aims and objectives is to study effectiveness of addition of drug Teneligliptin to Metformin, Glimepiride, Pioglitazone combination in Type II Diabetic patients.

Methods: This was a cross-sectional study carried out in the department of Medicine of a tertiary health care centre during the one-year period i.e. January 2017 to January 2018 in the Type II diabetic patients. Out of all Type II diabetic patients 40 patients who were on the treatment for hypoglycemia with drugs Metformin, Glimepiride, Pioglitazone were selected out of these randomly 20 patients were continued on the previous treatment (Group B) and remaining 20 were given additional drug Teneligliptin (Group A). The statistical analysis was done by unpaired t-test and chi-square test analyzed by SPSS 19 version of software.

Results: In this study Authors have seen that the average age in both the groups was comparable i.e. 36.78±6.74 and 38.92±5.87 (p>0.05, t=1.24, df=38), the sex ratio was also similar in both the group (p>0.43, χ²=0.43, df=1) and the HbA1C was comparable at th 1st Wk. 10±4.56 - 9.87±3.42 (p>0.05, t=1.023, df=38) and th 4th Wk. 8±5.23 - 9.67±4.52 (p>0.05, t=1.0804, df=38) but significantly differed at th 8th Wk. 7.12±2.34 - 9.92±3.56 (p<0.01, t=3.82, df=38), 12th Wk. 5.98±1.98 - 9.24±2.79 (p<0.001, t=4.26, df=38) respectively in Group A and B.

Conclusions: It can be concluded from this study that the addition of Teneligliptin significantly reduced the HbA1C level at the end of 4th wk. and hence superior to conventional Metformin, Glimepiride, Pioglitazone only combination treatment.

Keywords: Glimepiride, Metformin, Pioglitazone, Teneligliptin, Type II diabetes

INTRODUCTION

Diabetes is a most prevalent chronic disease and has reached to alarming stage in almost all developed and developing countries. Worldwide approximately four hundred millions of people are living with diabetes and it is a leading cause of death. This number is expected to rise to 642 million by 2040. A mortality burden of 5 million was noted with diabetes.1 Diabetes affects many organs and complications due to high blood glucose are an important cause of disability, reduced quality of life, and premature death.1 In 2015, globally, ~5 million people aged between 20 years and 79 years died due to diabetes; this accounts for one death every 6 seconds.1 Diabetes is a chronic disease that requires lifelong medical care and attention for multiple risk reduction and treatment approach beyond glycemic control.2 Treatment objective must be the prevention of short-term and long-term complications associated with diabetes.3 Additionally, patient education and support are important.
aspects. This will improve patient outcomes. A multidisciplinary approach is required for the management of diabetes. Considering the huge epidemic of type 2 diabetes mellitus (T2DM), newer therapies that improve efficacy, tolerability, and long-term compliance and prevent complications associated with T2DM are always required and preferred. Recently, a new and relatively economic dipeptidyl peptidase 4 (DPP-4) inhibitor, teneligliptin, has been made available in some countries such as Japan (Teneria), Argentina (Teneglucon®), and India (Tenepure; Teneza). Authors have studied the effectiveness of teneligliptin with respect to glycemia in the management of T2DM.

**METHODS**

This was a cross sectional study carried out in the department of Medicine of a tertiary health care centre during the one year period i.e. January 2017 to January 2018 in the type II diabetic patients. Out of all type II diabetic patients 40 patients who were on the treatment for hypoglycaemia with drugs Metformin, Glimepiride, Pioglitazone were selected out of these randomly 20 patients were continued on the previous treatment (Group B) and remaining 20 were given additional drug Teneligliptin (Group A). The glycaemic control was monitored with respect to glycosylated Hb (HbA1C) at 1st Wk, 4th Wk, 8th Wk, 12th Wk. after starting the treatment. The statistical analysis was done by unpaired t-test and chi-square test analysed by SPSS 19 version of software.

**Inclusion criteria**

- Patients with type 2DM not adequately controlled with triple drug (Metformin, Glimepiride, Pioglitazone).

**Exclusion criteria**

- Patients with type 2DM with comorbidities like renal failure, ischemic heart disease with congestive cardiac failure, diabetic nephropathy.

**RESULTS**

Total 40 patients divided in two groups A and B as shown in table 1, the mean age in group A was 36.78 with standard deviation of 6.74 and in group B mean age was 38.92 with standard deviation 5.87.

| Group A (20) | Group B (20) | p-value |
|--------------|--------------|---------|
| Average age (Mean±SD) | 36.78±6.74 | 38.92±5.87 | p>0.05, t=1.24, df=38 |
| Sex | Male | 12 | 14 | p>0.43, χ²=0.43, df=1 |
| | Female | 8 | 6 | |

**Table 1: Distribution of the patients as per the socio demographic characters.**

| Post treatment duration (Wks.) | Group A (20) | Group B (20) | p-value |
|-------------------------------|--------------|--------------|---------|
| 1st Wk. | 10±4.56 | 9.87±3.42 | p>0.05, t=1.023, df=38 |
| 4th Wk. | 8±5.23 | 9.67±4.52 | p>0.05, t=1.0804, df=38 |
| 8th Wk. | 7.12 ± 2.34 | 9.92±3.56 | p<0.01, t=3.82, df=38, |
| 12th Wk. | 5.98±1.98 | 9.24±2.79 | p<0.001, t=4.26, df=38, |

| Group A (20) | Group B (20) | p-value |
|--------------|--------------|---------|
| 1st Wk. | 10±4.56 | 9.87±3.42 | p>0.05, t=1.023, df=38 |
| 4th Wk. | 8±5.23 | 9.67±4.52 | p>0.05, t=1.0804, df=38 |
| 8th Wk. | 7.12±2.34 | 9.92±3.56 | p<0.01, t=3.82, df=38 |
| 12th Wk. | 5.98±1.98 | 9.24±2.79 | p<0.001, t=4.26, df=38, |

It shows that the average age in both the groups was comparable i.e. 36.78±6.74 and 38.92±5.87 (p>0.05, t=1.24, df=38). There were 12 male and 8 female in group A, 14 male and 6 female in group B. Nearly equal no of male and female patients were there, the sex ration was also similar in both the groups (p>0.43, χ²=0.43, df=1).

As shown in table 2 the baseline (1st week) HbA1c in both group was nearly equal, 10 and 9.87 in group A and B respectively. There was marginal reduction at the end of 4th week in group A as compared to group B. The further fall in HbA1c was observed at the end of 8th week 7.12 (group A) but was not seen in group B. At the end of 12th week group A showed fairly well controlled HbA1c.

In brief the HbA1C was comparable at 1st Wk. 10±4.56 - 9.87±3.42 (p>0.05, t=1.023, df=38 ) and 4th Wk. 8±5.23 - 9.67±4.52 (p>0.05, t=1.0804, df=38 ) but significantly differed at 8th Wk. 7.12±2.34 - 9.92±3.56 (p<0.01, t=3.82, df=38), 12th Wk. 5.98±1.98- 9.24±2.79 (p<0.001, t=4.26, df=38) respectively in Group A and B.

This study shows that addition of 4th drug as teneligliptin in patients with type 2DM not having adequate glycaemic control with triple drug combination(Metformin, Glimepiride, Pioglitazone).
Glimepiride, Pioglitazone reduces HbA1c significantly and bring patient in acceptable glycaemic control.

**DISCUSSION**

Incretin hormones are released by the small intestine in response to a meal. One of these incretins, glucagon-like peptide-1 (GLP-1), plays a critical role in the regulation of postprandial glucose (PPG) by stimulating insulin secretion and inhibiting glucagon secretion in a glucose dependent manner. However, as GLP-1 is rapidly degraded by dipeptidyl peptidase-4 (DPP-4), DPP-4 inhibitors were developed to increase the endogenous GLP-1 levels, and hence lower blood glucose levels in a glucose-dependent manner. Eto T. et al. previously reported that once-daily administration of teneligliptin significantly increased postprandial plasma levels of active GLP-1 in type 2 diabetes mellitus (T2DM) patients and that the PPG-lowering effects of once-daily teneligliptin were sustained throughout the day. T. Kadowaki have also found that teneligliptin monotherapy achieved significant reductions in haemoglobin A1c (HbA1c) [placebo-subtracted least-squares (LS) mean change: -0.9, -0.9 and -1.0% for 10, 20 and 40 mg teneligliptin, respectively; all, p <0.001] and fasting plasma glucose (FGP) levels (-17.8, -16.9 and -20.0 mg/dl, respectively), and was generally well tolerated in Japanese patients with T2DM. Sulphonylureas are widely used because of their low price and their well-established efficacy and safety. Furthermore, they are often used as the initial antidiabetic drug in Japan. However, sulphonylureas do require some special attention because of the risk of hypoglycaemia and weight gain, together with their limited durability in clinical use. Both incretin-related drugs and sulphonylureas stimulate insulin secretion from pancreatic β-cells through independent pathways, although there is some evidence to suggest that both pathways may incorporate Epac2, a cAMP sensor, which may mediate some of the effects of both classes of drugs on insulin secretion. Therefore, administration of a sulphonylurea in combination with an incretin-related drug is potentially very useful, and many studies have tested combinations of these drugs.

In this study Authors have seen that The average age in both the groups was comparable i.e. 36.78±6.74 and 38.92±5.87 (p>0.05, t=1.24, df=38), the sex ration was also similar in both the group (p=0.43, χ²=0.43, df=1) and The HbA1c was comparable at 1st Wk. 10±4.56 - 9.87±3.42 (p>0.05, t=1.023, df=38) and 4th Wk. 8±5.23 - 9.67±4.52 (p>0.05, t=1.0804, df=38 ) but significantly differed at 8th Wk. 7.12±2.34 - 9.92±3.56 (p<0.01, t=3.82, df=38), 12th Wk. 5.98±1.98 - 9.24±2.79 (p<0.001, t=4.26 ,df=38) respectively in Group A and B. This was similar to Meta-analysis done by T. Kadowaki they found Teneligliptin reduced HbA1c significantly compared with placebo at week 12. The placebo-subtracted change in HbA1c was -1.0±0.1% [least-squares (LS) Means±SE., p <0.001].

**CONCLUSION**

It can be concluded from this study that the addition of Teneligliptin significantly reduced the HbA1C level at the end of 4th wk, and hence superior to conventional Metformin, Glimepiride, Pioglitazone only combination treatment. Patients of type 2DM who are not adequately controlled with conventional triple drug combination and not willing for insulin therapy can be given Teneligliptin as add on therapy.

**ACKNOWLEDGEMENTS**

Authors would like to thank Dr. Sumanth MM, Assistant Professor, Department of Community Medicine, M.M.C and R.I., Mysore for assisting with the statistical work.

**Funding: No funding sources**

**Conflict of interest: None declared**

**Ethical approval: The study was approved by the Institutional Ethics Committee**

**REFERENCES**

1. Atlas D. International diabetes federation. IDF Diabetes Atlas, 7th edn. Brussels, Belgium: International Diabetes Federation. 2015.
2. American Diabetes Association. 1. Strategies for improving care. Diab care. 2016 Jan 1;39(Supplement 1):S6-12.
3. American Diabetes Association. 3. Foundations of care and comprehensive medical evaluation. Diab Care. 2016 Jan 1;39(Supplement 1):S23-35.
4. Majumdar SK, Inzucchi SE. Investigational anti-hyperglycemic agents: the future of type 2 diabetes therapy? Endocrine. 2013 Aug 1;44(1):47-58.
5. Kishimoto M. Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes. Metab Synd Obes: Targ Ther. 2013:6:187.
6. Scott LJ. Teneligliptin: a review in type 2 diabetes. Clni Drug Invest. 2015 Nov 1;35(11):765-72.
7. Sharma SK, Panneerselvam A, Singh KP, Parmar G, Gadge P, Swarn OC. Diabetes, Metab Synd Obes: Targ Ther. 2016;9:251.
8. Kreymann B, Ghatei MA, Williams G, Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet. 1987 Dec 5;330(8571):1300-4.
9. Edwards CM, Todd JF, Mahmoudi M, Wang Z, Wang RM, Ghatei MA, et al. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes. 1999 Jan 1;48(1):86-93.
10. Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Wills M, Holst JJ. Both subcutaneously and intravenously administered glucagon-like peptide 1
are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes. 1995 Sep 1;44(9):1126-31.
11. Holst JJ, Deacon CF. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes. 1998 Nov 1;47(11):1663-70.
12. Eto T, Inoue S, Kadowaki T. Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial. Diabetes, Obes Metab. 2012 Nov;14(11):1040-6.
13. Kadowaki T, Kondo K. Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Diabetes, Obes Metab. 2013 Sep;15(9):810-8.
14. Neville SE, Boye KS, Montgomery WS, Iwamoto K, Okamura M, Hayes RP. Diabetes in Japan: a review of disease burden and approaches to treatment. Diabetes/ Metab Res Rev. 2009 Nov;25(8):705-16.
15. Idris I, Donnelly R. Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug. Diabetes, Obes Metab. 2007 Mar;9(2):153-65.
16. Del Prato S, Pulizzi N. The place of sulfonylureas in the therapy for type 2 diabetes mellitus. Metabolism. 2006 May 1;55:S20-7.
17. Zhang CL, Katoh M, Shibasaki T, Minami K, Sunaga Y, Takahashi H, et al. The cAMP sensor Epac2 is a direct target of antidiabetic sulfonylurea drugs. Science. 2009 Jul 31;325(5940):607-10.
18. Tajima N, Kadowaki T, Odawara M, Nishii M, Taniguchi T, Ferreira JC. Addition of sitagliptin to ongoing glimepiride therapy in Japanese patients with type 2 diabetes over 52 weeks leads to improved glycemic control. Diabetol Int. 2011 Mar 1;2(1):32-44.
19. Kikuchi M, Haneda M, Koya D, Tobe K, Onishi Y, Couturier A, et al. Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2010 Sep 1;89(3):216-23.
20. Kadowaki T, Kondo K. Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension. Diabetes, Obes Metab. 2014 May;16(5):418-25.

Cite this article as: Patil DP. A study of effectiveness of addition of drug teneligliptin to metformin, glimepiride, pioglitazone combination in type II diabetic patients. Int J Res Med Sci 2020;8:692-5.